ThromboVision Receives First DeBakey Life Science Award and joins HTC to Accelerate Growth
ThromboVision was chosen from a field of 18 for the award, which carries a $50,000 cash prize to assist in propelling the company’s technology toward commercial success.
The award was presented to ThromboVision’s president and CEO, Edward R. Teitel, MD, JD, MBA, by Dr. DeBakey; Malcolm Gillis, PhD, BioHouston chairman; and John Mendelsohn, MD, president, The University of Texas M.D. Anderson Cancer Center, at BioHouston’s 2006 Texas Life Science Conference.
ThromboVision’s initial product, currently in late-stage development, is a platelet function monitor called the ThromboGuide (T-GuideTM). This device will help physicians individualize antiplatelet therapy when they treat cardiovascular patients for heart attacks, strokes and stent occlusions.
“We’re in this business to save lives, ” said Dr. Teitel. “The sooner we can submit our system to the FDA for approval to market, the sooner we can help physicians improve their patients’ care. We expect that access to the HTC’s high-level planning expertise and potential funding sources will accelerate our growth model.”
ThromboVision, Inc. is a biomedical company committed to enabling people to lead longer and healthier lives. ThromboVision provides easy-to-use, rapid-response, cost-effective, and versatile point-of-care clinical diagnostic discoveries that advance medical diagnosis. The company’s products will improve medical care by assisting physicians in diagnosing and managing critical cardiovascular risk modification factors. www.thrombovision.com
BioHouston, Inc., was founded by Houston-region academic/research institutions to help establish the
ABOUT HOUSTON TECHNOLOGY CENTER
Houston Technology Center (HTC) is a business accelerator that assists Houston-based emerging technology companies in key sectors such as Energy, Information Technology, Life Sciences, Nanotechnology and NASA-originated technologies. www.houstontech.org
SAFE HARBOR STATEMENT
This release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Statements in this release regarding ThromboVision’s business that are not historical facts are “forward-looking statements,” which involve risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements.